Thrombosis associated with cancer (CAT): paradigm change, a review of the literature
DOI:
https://doi.org/10.35509/01239015.766Keywords:
cancer associated thrombosis, treatment, direct oral Anticoagulants, arterial thrombotic events, cancer type, stage, chemotherapeutic, Risk factors, thrombosisAbstract
Cancer-associated thrombosis is one of the main causes of morbidity and mortality in cancer patients; it has an incidence of 13.9 per 1000 person years, representing the second cause of mortality in this group of patients. Due to advances in understanding the pathophysiology of cancer and the increasingly strong evidence in favor of new directacting oral anticoagulants over other anticoagulants, a change has been developed in the management paradigm forpatients with this condition, which in the long run is reflected in better adherence and lower treatment costs, as well as an improvement in the quality of life of these patients. Despite this, due to the complexity of the cancer patient, it is good practice to individualize each patient, giving them the management that best suits their needs.
References
Streiff M, Abutalib S, Farge D, Murphy M , Connors JM , Piazza G. Update on Guidelines for the Management of Cancer-AssociatedThrombosis. The Oncologist. 2021;26:e24-40. https://doi.org/10.1002/onco.13596.
Chew HK, Wun T, Harvey D, Zhou H, White RH. Incidence of venous thromboembolism and its effect on survival among patients with common cancers. Arch Intern Med. 2006;166(458). https://doi.org/10.1001/archinte.166.4.458.
Alcalay A, Wun T, Khatri V, Chew HK, Harvey D, Zhou H, White RH. Venous thromboembolism in patients with colorectal cancer: incidence and effect on survival. J Clin Oncol. 2006;24(1112). https://doi.org/10.1200/JCO.2005.04.2150.
Yu YB, Gau JP, Liu CY, Yang MH, Chiang SC, Hsu HC et al. A nation-wide analysis of venous thromboembolism in 497,180 cancer patients with the development and validation of a risk-stratification scoring system. Thromb Haemost. 2012;108(225). https://doi.org/10.1160/TH12-01-0010.
Perilla Suárez O. Caracterización clínica de pacientes con enfermedad tromboembólica asociada a cáncer en el Instituto Nacional de Cancerología. Universidad Nacional de Colombia Sede Bogotá Facultad de Medicina Departamento de Medicina Interna, 2018. https://repositorio.unal.edu.co/handle/unal/62885
Mukai M, Oka T. Mechanism and management of cancerassociated thrombosis. Journal of Cardiology. 2018;72:89-93. https://doi.org/10.1016/j.jjcc.2018.02.011.
Sharma BK, Flick M, Palumbo J. Cancer-Associated Thrombosis: A Two-Way Street. Semin Thromb Hemost. 2019;45(6):559-68. https://doi.org/10.1055/s-0039-1693472.
Mahajan A, Brunson A, White R, Wun T. The Epidemiology ofCancer-Associated Venous Thromboembolism: An Update. Semin Thromb Hemost. 2019;45(4):321-5. https://doi. org/10.1055/s-0039-1688494.
Soff G. Thrombosis and Hemostasis in Cancer. Scope of the Problem and Overview. Cancer treatment and research. 2019;179:1-9. https://doi.org/10.1007/978-3-030-20315-3_1.
Lacroix R, Vallier L, Bonifay A, Simoncini S, Mege D, Aubert M et al. Microvesicles and Cancer Associated Thrombosis. Semin Thromb Hemost.2019; 45(6): 593-603. https://doi.org/10.1055/s-0039-1693476.
Aronson D, Brenner B. Arterial thrombosis and cancer. Thromb Res. 2018;164 Suppl(1):S23-8. https://doi.org/10.1016/j.thromres.2018.01.003.
Jiang M, Li C, Pan C, Cui X, Dietrich C. Risk of venous thromboembolism associated with totally implantable venous access ports in cancer patients: A systematic review and meta-analysis. J Thromb Haemost. 2020;18(9):2253-2273. https://doi.org/10.1111/jth.14930.
Ageno W, Haas S, Weitz JI, Goldhaber SZ, Turpie AGG, Goto S, et al. Upper Extremity DVT versus Lower Extremity DVT: Perspectives from the GARFIELD-VTE Registry. Thromb Haemost. 2019;119(8):1365-1372. https://doi.org/10.1055/s-0039-1688828.
Sevestre M, Soudet S. Epidemiology and risk factors for cancer-associated thrombosis. J Med Vasc. 2020;45(6S):6S3-6S7. https://doi.org/10.1016/S2542-4513(20)30513-7.
Abdol Razak N, Jones G, Bhandari M, Berndt M, Metharom P. Cancer-Associated Thrombosis: An Overview of Mechanisms, Risk Factors, and Treatment. Cancers (Basel). 2018;10(10):380. https://doi.org/10.3390/cancers10100380.
Eichinger S. Cancer associated thrombosis: risk factors and outcomes. Thromb Res. 2016;140(Suppl 1):S12-7. https://doi.org/10.1016/S0049-3848(16)30092-5.
Campello E, Henderson M, Noubouossie D, Simioni P, Key N. Contact System Activation and Cancer: New Insights in thePathophysiology of CancerAssociated Thrombosis. Thromb Haemost. 2018;118(2):251-65. https://doi.org/10.1160/TH17-08-0596.
Soff GA. Pathophysiology and management of thrombosis in cancer: 150 years of progress. Thromb Thrombolysis. 2013;35(346–351). https://doi.org/10.1007/s11239-013-0897-9.
Hisada Y, Mackman N. Cancer-associated pathways and biomarkers of venous thrombosis. Blood. 2017;130(13):1499-1506. https://doi.org/10.1182/blood-2017-03-743211.
Mege D, Aubert M, Lacroix R, Dignat-George F, Panicot-Dubois L, Dubois C. Involvement of Platelets in Cancers. Seminars in Thrombosis and Hemostasis.Thieme Publishing, 2019, 45 (06);569-575. https://doi.org/10.1055/s-0039-1693475
Boccaccio C, Sabatino G, Medico E, Girolami F, Follenzi A, Reato G, et al. The MET oncogene drives a genetic programme linking cancer to haemostasis. Nature. 2005;434(7031):396-400. https://doi.org/10.1038/nature03357.
García E, Luengo-Gil G, de la Morena P, Ayala F. Microvesículas en cáncer de mama. Rev Senol Patol Mamar. 2016;29(3):125-31. https://doi.org/10.1016/j.senol.2016.06.005
Kim A, Khorana A, McCrae K. Mechanisms and biomarkers of cancer-associated thrombosis. Transl Res. 2020;(225):33-53. https://doi.org/10.1016/j.trsl.2020.06.012.
Semenza G. Hypoxia-inducible factors: mediators of cancer progression and targets for cancer therapy. Trends Pharmacol Sci. 2012;33(4):207-214. https://doi.org/10.1016/j.tips.2012.01.005.
Evans C, Bendahl P, Belting M, Branco C, Johnson R. Diverse roles of cell-specific hypoxia-inducible factor 1 in cancerassociated hypercoagulation. Blood. 2016;127(10):1355-1360. https://doi.org/10.1182/blood2015-09-671982.
Thålin C, Hisada Y, Lundström S, Mackman N, Wallén H. Neutrophil Extracellular Traps: Villains and Targets in Arterial, Venous, and Cancer-Associated Thrombosis. Arterioscler Thromb Vasc Biol . 2019;39(9):1724-38. https://doi.org/10.1161/ATVBAHA.119.312463.
Xue J, Xie VK, Wang P, Cui J, Gao Y, Lu Z. Interrelationships of Circulating Tumor Cells with Metastasis and Thrombosis: Role of MicroRNAs. Curr Pharm Des. 2014;20(33):5298-5308. https://doi.org/10.2174/1381612820666140128220152.
Li X, Dong M, Zang X, Li MY, Zhou JY, Ma JJ, Wang GY. The emerging role of circulating tumor cells in cancer management. Am J Transl Res. 2020; 12(2):332-42. /ISSN:1943-8141/AJTR0101663
Akpe V, Kim T, Brown C, Cock I. Circulating tumour cells: a broad perspective. J R Soc Interface.2020. 17: 20200065. https://doi.org/10.1098/rsif.2020.0065
Richmond J, Gilbar P, Abro E. Gemcitabine-induced thrombotic microangiopathy. Intern Med J. 2013;43(11):1240-2. https://doi.org/10.1111/imj.12261.
Jiang D, Lee A. Thrombotic Risk from Chemotherapy and Other Cancer Therapies. Cancer Treat Res. 2019;179:87-101. https://doi.org/10.1007/978-3-030-20315-3_6.
Khorana A, Carrier M, Garcia D, Lee A. Guidance for the prevention and treatment of cancer-associated venous thromboembolism. J Thromb Thrombolysis. 2016;41(1):81-91. https://doi.org/10.1007/s11239-015-1313-4.
Scotté F, Leroy P, Chastenet M, Aumont L, Benatar V, Elalamy I. Treatment and Prevention of Cancer-Associated Thrombosis in Frail Patients: Tailored Management. Cancers (Basel). 2019;11(1):48. https://doi.org/10.3390/cancers11010048.
Sanfilippo K, Wang T. Prevention and Treatment of Cancer-Associated Venous Thromboembolism: a Review. Curr Treat Options Cardiovasc Med. 2019;21(11):70. https://doi.org/10.1007/s11936-019-0764-x.
Farge D, Frere C, Connors JM, Ay C, Khorana AA, Munoz A, et al. 2019 international clinical practice guidelines for the treatment and prophylaxis of venous thromboembolism in patients with cancer. Lancet Oncol. 2019;20(10):e566-e581. https://doi.org/10.1016/S1470-2045(19)30336-5.
Klerk CP, Smorenburg SM, Otten HM, Lensing AW, Prins MH, Piovella F,, et al. The effect of low molecular weight heparin on survival in patients with advanced malignancy. J Clin Oncol. 2005;23(10):2130-5. https://doi.org/10.1200/JCO.2005.03.134.
Bochenek J, Püsküllüoğlu M, Krzemieniecki K. The antineoplastic effect of low-molecular-weight heparins - a literature review. Contemp Oncol (Pozn). 2013;17(1):6-13. https://doi.org/10.5114/wo.2013.33766.
Ma SN, Mao ZX, Wu Y, Liang MX, Wang DD, Chen X, et al. The anti-cancer properties of heparin and its derivatives: a review and prospect. Cell Adh Migr. 2020;14(1):118-28. https://doi.org/10.1080/19336918.2020.1767489.
Büller HR, Davidson BL, Decousus H, Gallus A, Gent M, Piovella F, et al. Fondaparinux or enoxaparin for the initial treatment of symptomatic deep venous thrombosis: a randomized trial. Ann Intern Med. 2004;140(11):867-73. https://doi.org/10.7326/0003-4819-140-11-200406010-00007.
Streiff M. Thrombosis in the setting of cancer. Hematology Am Soc Hematol Educ Program. 2016;2016(1):196-205. https://doi.org/10.1182/asheducation-2016.1.196.
Moik F, Posch F, Zielinski C, Pabinger I, Ay C. Direct oral anticoagulants compared to low‐molecular‐weight heparin for the treatment of cancer‐associated thrombosis: Updated systematic review and meta‐analysis of randomized controlled trials. Res Pract Thromb Haemost. 2020;(4):550-61. https://doi.org/10.1002/rth2.12359.
van Doormaal FF, Raskob GE, Davidson BL, Decousus H, Gallus A, Lensing AW, et al. Treatment of venous thromboembolism in patients with cancer: subgroup analysis of the Matisse clinical trials. Thromb Haemost. 2009;101(4):762-769. PMID:19350123
Franco-Moreno A, Cabezón-Gutiérrez L, Palka-Kotlowsa M, Villamayor-Delgado M, García-Navarro M. Evaluation of direct oral anticoagulants for the treatment of cancer-associated thrombosis: an update. J Thromb Thrombolysis. 2019;47(3):409-19. https://doi.org/10.1007/s11239-018-1783-2.
Suryanarayan D, Lee A, Wu C. Direct Oral Anticoagulants in Cancer Patients. Semin Thromb Hemost. 2019;45(6):638-647. https://doi.org/10.1055/s-0039-1693479.
Moik F, Ay C. How I Manage Cancer-Associated Thrombosis. Hamostaseologie. 2020;40(1):38-46. https://doi.org/10.1055/s-0039-3402806.
Farge D, Bounameaux H, Brenner B, Cajfinger F, Debourdeau P, Khorana AA,, Et al. International clinical practice guidelines including guidance for direct oral anticoagulants in the treatment and prophylaxis of venous thromboembolism in patients with cancer. Lancet Oncol. 2016;17(10):e452-e466. https://doi.org/10.1016/S1470-2045(16)30369-2.
Elalamy I, Mahé I, Ageno W, Meyer G. Long-term treatment of cancer-associated thrombosis: the choice of the optimal anticoagulant. J Thromb Haemost. 2017;15(5):848-57. https://doi.org/10.1111/jth.13659.
Song A, Rosovsky R, Connors J, Al-Samkari H. Direct oral anticoagulants for treatment and prevention of venous thromboembolism in cancer patients. Vascular Health and Risk Management. 2019;15:175-186. https://doi.org/10.2147/VHRM.S132556.
Rafii H, Frère C, Benzidia I, Crichi B, Andre T, Assenat E, et al. Management of cancer-related thrombosis in the era of direct oral anticoagulants: A comprehensive review of the 2019 ITAC-CME clinical practice guidelines. On behalf of the Groupe Francophone Thrombose et Cancer (GFTC). J Med Vasc. 2020;45(1):28-40. https://doi.org/10.1016/j.jdmv.2019.12.004
Hutchinson A, Rees S, Young A, Maraveyas A, Date K, Johnson MJ. Oral anticoagulation is preferable to injected, but only if it is safe and effective: An interview study of patient and carer experience of oral and injected anticoagulant therapy for cancer-associated thrombosis in the select-d trial. Palliat Med. 2019;33(5):510-517. https://doi.org/10.1177/0269216318815377.
Young AM, Marshall A, Thirlwall J, Chapman O, Lokare A, Hill C, et al. Comparison of an Oral Factor Xa Inhibitor With Low Molecular Weight Heparin in Patients With Cancer With Venous Thromboembolism: Results of a Randomized Trial (SELECT-D). J Clin Oncol. 2018;10(36):2017-2023. https://doi.org/10.1200/JCO.2018.78.8034.
McBane RD 2nd, Wysokinski WE, Le-Rademacher JG, Zemla T, Ashrani A, Tafur A,, et al. Apixaban and dalteparin in active malignancy-associated venous thromboembolism: The ADAM VTE trial. J Thromb Haemost. 2020;18(2):411-21. https://doi.org/10.1111/jth.14662.
Stebler-Fontaine L, Rossel A, Marti C, Righini M, Robert-Ebadi H. Direct oral anticoagulants in the treatment of cancerassociated thrombosis. Rev Med Suisse. 2019;15(674):2232-2235. PMID: 31804034.
Giustozzi M, Agnelli G, Del Toro-Cervera J, Klok FA, Rosovsky RP, Martin AC, et al. Direct Oral Anticoagulants for the Treatment of Acute Venous Thromboembolism Associated with Cancer: A Systematic Review and Meta-Analysis. Thromb Haemost. 2020;120(7):1128-36. https://doi.org/10.1055/s-0040-1712098.
Ay C, Beyer-Westendorf J, Pabinger I. Treatment of cancerassociated venous thromboembolism in the age of direct oral anticoagulants. Ann Oncol. 2019;30(6):897-907. https://doi.org/10.1093/annonc/mdz111.
Agnelli G, Becattini C, Meyer G, et al. Apixaban for the Treatment of Venous Thromboembolism Associated with Cancer: The Caravaggio Study. N Engl J Med. 2020;382(17):1599-607. https://doi.org/10.1056/NEJMoa1915103
Li A, Garcia D, Lyman G, Carrier M. Direct oral anticoagulant (DOAC) versus low-molecular-weight heparin (LMWH) for treatment of cancer associated thrombosis (CAT): A systematic review and meta-analysis. Thromb Res. 2019;173:158-63. https://doi.org/10.1016/j.thromres.2018.02.144.
Haykal T, Zayed Y, Deliwala S, Kerbage J, Ponnapalli A, Malladi S, et al. Direct oral anticoagulant versus low-molecularweight heparin for treatment of venous thromboembolism in cancer patients: An updated meta-analysis of randomized controlled trials. Thromb Res. 2020;18(194):57-65. https://doi.org/10.1016/j.thromres.2020.06.025.
Haykal T, Adam S, Ortel T. Meta-analysis fever in the wake of CARAVAGGIO. Thromb Res. 2020;26(196):141-2. https://doi.org/10.1016/j.thromres.2020.08.036.
Mulder FI, Bosch FTM, Young AM, Marshall A, McBane RD, Zemla TJ, et al. Direct oral anticoagulants for treatment of cancerassociated venous thromboembolism: A systematic review and meta-analysis. Blood. 2020;136(17):1433-41. https://doi.org/10.1182/blood.2020005819.
Saleem M, Osman M. Farid S, Bianco CM, Patel B, Michos E, et al.Direct oral anticoagulants for treatment of venous thromboembolism associated with cancer: a systematic review and meta-analysis. Clinical Oncology and Research. 2020;3(6):1-7. https://doi.org/10.31487/j.COR.2020.06.14
Tao D, Olson S, DeLoughery T, Shatzel J. The efficacy and safety of DOACs versus LMWH for cancer-associated thrombosis: a systematic review and meta-analysis. Eur J Haematol. 2020;3(360-362). https://doi.org/10.1111/ejh.13453.
Riess H, Verhamme P, Weitz JI, Young A, Bauersachs R, Beyer-Westendorf J, et al. Treatment of cancer-associated thrombosis: The evolution of anticoagulant choice and clinical insights into practical management. Crit Rev Oncol Hematol. 2020;(157):103-25. https://doi.org/10.1016/j.critrevonc.2020.103125.
Bauersachs R, Khorana A, Lee A, Soff G. Cancer-associated venous thromboembolism: Treatment and prevention with rivaroxaban. Res Pract Thromb Haemost. 2020;4(4):532-49. https://doi.org/10.1002/rth2.12327.
Raskob G, Van Es N, Verhamme P, Carrier M, Di Nisio M, Garcia D, et al. Edoxaban for the Treatment of Cancer-Associated VenousThromboembolism. NEJM. 2018;378(7):615-24. https://doi.org/10.1056/NEJMoa1711948
Venous thromboembolic diseases: diagnosis, management and thrombophilia testing. NICE guideline(2020)[NG158]Published: 26 March 2020 67. Mahé I, Elalamy I, Gerotziafas G, Girard P. Treatment of Cancer-Associated Thrombosis: Beyond HOKUSAI. 2019; 16;3(3):. doi: TH Open. 2019;16(3):e309-15. https://doi.org/10.1055/s-0039-1696659.
Ramacciotti E, Agati L, Caffaro R, Volpiani G, Lopes R, Comerota A, et al. Direct Oral Anticoagulants and Cancer-Associated Thrombosis Management. Where Do We Stand in 2019? Clin Appl Thromb Hemost. enero de 2019;(25):1076029619856433. https://doi.org/10.1177/1076029619856433.
Marin-Romero S, Jara-Palomares L. Extended treatment of cancer-associated thrombosis. Thromb Res. 2019;181:1-9. https://doi.org/10.1016/j.thromres.2019.07.003.
Streiff MB, Agnelli G, Connors JM, Crowther M, Eichinger S, Lopes R, Streiff M, Agnelli G, et al. Guidance for the treatment of deep vein thrombosis and pulmonary embolism. J Thromb Thrombolysis. 2016;41(1):32-67. https://doi.org/10.1007/s11239-015-1317-0.
Kahale LA, Hakoum MB, Tsolakian IG, Matar CF, Terrenato I, Sperati F, et al. Anticoagulation for the long-term treatment of venous thromboembolism in people with cancer. Cochrane Database Syst Rev. 2018;6(6):CD006650. https://doi.org/10.1002/14651858.CD006650.pub5.
Swan D, Rocci A, Bradbury C, Thachil J. Venous thromboembolism in multiple myeloma - choice of prophylaxis, role of direct oral anticoagulants and special considerations. Br J Haematol. 2018;183(4):538-56. https://doi.org/10.1111/bjh.15684.
Cornell RF, Goldhaber SZ, Engelhardt BG, Moslehi J, Jagasia M, Harrell S, et al. Primary prevention of venous thromboembolism with apixaban for multiple myeloma patients receiving immunomodulatory agents. Br J Haematol. 2020;190(4):555-61. https://doi.org/10.1111/bjh.16653.
Tsoukalas N, Tsapakidis K, Galanopoulos M, Karamitrousis E, Kamposioras K, Tolia M.Tsoukalas N, Tsapakidis K, Galanopoulos M, et al. Real world data regarding the management of cancer-associated thrombosis. Curr Opin Oncol. 2020;32(4):289-94. https://doi.org/10.1097/CCO.0000000000000646.
Khorana AA, McCrae KR, Milentijevic D, Fortier J, Nelson WW, Laliberté F, et al. Duration of anticoagulant therapy and VTE recurrence in patients with cancer. Support Care Cancer. 2019;27(10):3833-40. https://doi.org/10.1007/s00520-019-4661-3.
McBane RD 2nd, Loprinzi CL, Ashrani A, Lenz CJ, Houghton D, Zemla T, et al. Extending venous thromboembolism secondary prevention with apixaban in cancer patients: The EVE trial. Eur J Haematol. 2020;104(2):88-96. https://doi.org/10.1111/ejh.13338.
Mulder FI, Candeloro M, Kamphuisen PW, Di Nisio M, Bossuyt PM, Guman N, et al. The Khorana score for prediction of venous thromboembolism in cancer patients: a systematic review and meta-analysis. Haematologica. 2019;104(6):1277-1287. https://doi.org/10.3324/haematol.2018.209114.
How to Cite
Downloads
Downloads
Published
Issue
Section
License
Copyright (c) 2022 Revista Colombiana de Cancerología
This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.
Todos los derechos reservados.
